Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2022-12-13 Director's Dealing
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice *5 12 pages 409.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and repeatedly references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including number of shares/options held before and after the change, nature of the change, and dates. The content is focused on personal share transactions by company directors, which aligns with insider trading or director dealings disclosures. There is no financial performance data, earnings information, or report publication announcements. The document is lengthy and detailed, not a brief announcement. Therefore, the document fits the category of Director's Dealing (DIRS).
2022-12-13 English
Notification regarding unquoted securities - BOT 7 pages 30.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted securities under an employee incentive scheme by Botanix Pharmaceuticals Ltd. It includes specifics such as the number of securities issued, issue dates, and mentions key management personnel involved. The content focuses on the issuance of securities and related compliance with ASX listing rules. There are no financial statements, earnings data, or management discussion of financial results. This fits the definition of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document length (6699 characters) and detailed issuance information confirm it is not a brief announcement or a report publication notice but a substantive notification of capital change.
2022-12-11 English
Application for quotation of securities - BOT 6 pages 27.6KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX by Botanix Pharmaceuticals Ltd. It details the number and type of securities to be quoted, issue dates, and distribution schedules. It references a previous Appendix 3B announcement related to the securities issuance. The document is focused on the listing and quotation of new securities rather than financial results, management changes, or other report types. This fits the category of Share Issue/Capital Change announcements, which cover new share issues and related capital changes. The document length is about 5,141 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-12-11 English
Notice under Section 708A(5)(e) of the Corporations Act 2 pages 160.4KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act, which relates to the issue of securities without disclosure under Part 6D.2 of the Corporations Act. It provides details about the securities issued, compliance with relevant provisions, and confirms no excluded information exists that would affect investors' assessment. The document is an announcement of a share issue and compliance notice rather than a full financial report or detailed financial data. It is short (4853 characters) and serves as a regulatory announcement about capital raising. Therefore, it fits best under Capital/Financing Update (CAP).
2022-12-11 English
Confirmation Sofpironium Bromide NDA Formally Under Review 3 pages 252.9KB
Capital/Financing Update Classification · 95% confidence The document is a press release dated 8 December 2022 from Botanix Pharmaceuticals announcing that the FDA has confirmed the New Drug Application (NDA) for Sofpironium Bromide is formally under review. It highlights key regulatory milestones such as acceptance of the NDA for substantive review, no advisory committee meeting required, and expected approval timeline. The document does not contain financial statements, detailed financial analysis, or comprehensive report data. It is an update on regulatory progress and FDA review status rather than a financial report or detailed investor presentation. The length is about 6,436 characters, which is relatively short and typical for a regulatory or capital/financing update. Given the content focuses on regulatory approval progress and milestones related to the NDA filing, the most appropriate classification is Capital/Financing Update (CAP), as it relates to a significant corporate development impacting the company's product pipeline and potential future revenue streams. It is not an earnings release, annual report, or other financial filing. Confidence is high due to clear regulatory and milestone update nature of the document.
2022-12-07 English
Application for quotation of securities - BOT 6 pages 27.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the number and type of securities to be quoted, issue dates, and issued capital following quotation. It references securities issued as part of a previously announced transaction (Appendix 3B). The content is focused on the issuance and quotation of new shares, not on financial results, management changes, or other report types. This fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital changes.
2022-11-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.